This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly (MIDA)

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Limoges Identifier:
First received: July 31, 2009
Last updated: March 19, 2014
Last verified: August 2009
In each of the 7 French areas that should be involved, patients aged 75 years and over from three different sectors will be included: the geriatric consultation unit (60%) and two kinds of nursing homes, private (20%) and state (10%). Outpatients will be included in chronological order; patients in nursing homes will be included at random. The patients and their families will be asked about the treatments received on the day of inclusion. The inclusion period will extend over a year. The investigating practitioners will be asked to fill in a questionnaire reporting the main clinical data, adverse effects occurrence, and information on the treatment given.

Alzheimer's Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Inappropriate Medications and Alzheimer Disease: Prevalence and Associated Factors in Elderly Patients Treated With Anticholinesterase and/or Memantine. MIDA Study.

Resource links provided by NLM:

Further study details as provided by University Hospital, Limoges:

Primary Outcome Measures:
  • To evaluate the prevalence of PIM use in patients aged 75 years and over treated with anticholinesterase and/or memantine [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • To identify factors associated with PIM use. To study the relationship between PIM exposure and adverse effects occurrence. [ Time Frame: 2 years ]

Enrollment: 636
Study Start Date: January 2009
Study Completion Date: January 2012
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   75 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patient of 75 and more years old affected by the Alzheimer's disease

Inclusion Criteria:

  • Patients aged 75 years and over identified as having Alzheimer disease and who have been treated for more than 3 months with anticholinesterase and/or memantine

Exclusion Criteria:

  • Patients with decompensated chronic condition or acute phase disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00954616

CHU Rouen
Rouen, Bois guillaume, France, 76 230
CHU Bordeaux
Pessac, Bordeaux, France, 33 604
CH Le Mans
Le Mans, Le Mans Cedex 1, France, 72 037
CHU Montpellier
Montpellier, Montpellier Cedex 5, France, 34 295
APHP Charles Foix
Ivry sur Seine, Paris, France, 94 205
CHU Saint Etienne
Saint Etienne, France, 42 055
Sponsors and Collaborators
University Hospital, Limoges
  More Information

Responsible Party: University Hospital, Limoges Identifier: NCT00954616     History of Changes
Other Study ID Numbers: I07033
Study First Received: July 31, 2009
Last Updated: March 19, 2014

Keywords provided by University Hospital, Limoges:
Inappropriate Medications Associated
Alzheimer's disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Enzyme Inhibitors
Cholinergic Agents processed this record on August 18, 2017